A citation-based method for searching scientific literature

Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
Times Cited: 123







List of co-cited articles
723 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, Kathleen R Lamborn, Andrew B Lassman, Susan M Chang, W K Alfred Yung, Mark R Gilbert, Howard A Fine, Minesh Mehta,[...]. J Neurooncol 2010
110
40

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
91
43

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
146
39

Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
36

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Derek R Johnson, David W Kimmel, Patrick A Burch, Terrence L Cascino, Caterina Giannini, Wenting Wu, Jan C Buckner. Neuro Oncol 2011
54
61

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
115
33

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
113
33

Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity.
Sara Arena, Federica Barbieri, Stefano Thellung, Paolo Pirani, Alessandro Corsaro, Valentina Villa, Patrizia Dadati, Alessandra Dorcaratto, Gabriella Lapertosa, Jean-Louis Ravetti,[...]. J Neurooncol 2004
76
39

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
44
68

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Warren P Mason, Fred Gentili, David R Macdonald, Subramanian Hariharan, Charlene R Cruz, Lauren E Abrey. J Neurosurg 2002
106
29

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
55
52

Salvage chemotherapy with CPT-11 for recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. J Neurooncol 2006
65
43


Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
132
28

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
U M Schrell, M G Rittig, M Anders, U H Koch, R Marschalek, F Kiesewetter, R Fahlbusch. J Neurosurg 1997
132
27

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
J W Goodwin, J Crowley, H J Eyre, B Stafford, K A Jaeckle, J J Townsend. J Neurooncol 1993
98
26

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
24



Non-resectable slow-growing meningiomas treated by hydroxyurea.
David Loven, Ruth Hardoff, Zvi Bar Sever, Adam P Steinmetz, Michael Gornish, Zvi H Rappaport, Eyal Fenig, Zvi Ram, Aaron Sulkes. J Neurooncol 2004
60
38

Medical therapies for meningiomas.
Patrick Y Wen, Eudocia Quant, Jan Drappatz, Rameen Beroukhim, Andrew D Norden. J Neurooncol 2010
103
23

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
David A Reardon, Andrew D Norden, Annick Desjardins, James J Vredenburgh, James E Herndon, April Coan, John H Sampson, Sridharan Gururangan, Katherine B Peters, Roger E McLendon,[...]. J Neurooncol 2012
50
46


Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
508
22

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala,[...]. J Neurooncol 2014
63
34

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
S E Kaba, F DeMonte, J M Bruner, A P Kyritsis, K A Jaeckle, V Levin, W K Yung. Neurosurgery 1997
96
20

Treatment of high risk or recurrent meningiomas with hydroxyurea.
Mark A Rosenthal, David L Ashley, Lawrence Cher. J Clin Neurosci 2002
50
40

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Steven M Grunberg, Martin H Weiss, Christy A Russell, Irving M Spitz, Jamshid Ahmadi, Alfredo Sadun, Regine Sitruk-Ware. Cancer Invest 2006
109
20




Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
393
18

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
67
26

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
56
32

Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
Barbara M Hahn, Ulrich M H Schrell, Rolf Sauer, Rudolf Fahlbusch, Oliver Ganslandt, Gerhard G Grabenbauer. J Neurooncol 2005
41
39

Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Thomas Graillon, Céline Defilles, Amira Mohamed, Christophe Lisbonis, Anne-Laure Germanetti, Olivier Chinot, Dominique Figarella-Branger, Pierre-Hugues Roche, Tarek Adetchessi, Stéphane Fuentes,[...]. J Neurooncol 2015
29
55

Hydroxyurea chemotherapy for unresectable or residual meningioma.
H B Newton, M A Slivka, C Stevens. J Neurooncol 2000
76
19


Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
S M Grunberg, M H Weiss, I M Spitz, J Ahmadi, A Sadun, C A Russell, L Lucci, L L Stevenson. J Neurosurg 1991
275
14

Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.
J W Koper, E C Zwarthoff, A Hagemeijer, R Braakman, C J Avezaat, M Bergström, S W Lamberts. Eur J Cancer 1991
49
28

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
608
14

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Julia Furtner, Veronika Schöpf, Katharina Seystahl, Emilie Le Rhun, Roberta Rudà, Ulrich Roelcke, Susanne Koeppen, Anna Sophie Berghoff, Christine Marosi, Paul Clement,[...]. Neuro Oncol 2016
40
35

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
14

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
357
14



Pathological classification and molecular genetics of meningiomas.
Christian Mawrin, Arie Perry. J Neurooncol 2010
270
13

Bevacizumab-induced regression of anaplastic meningioma.
M J A Puchner, V H Hans, A Harati, F Lohmann, M Glas, U Herrlinger. Ann Oncol 2010
52
25

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
322
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.